Version 1
: Received: 3 November 2023 / Approved: 6 November 2023 / Online: 6 November 2023 (10:38:14 CET)
How to cite:
Mustafa, M.; Alzebair, A.; Mohamednoor, H.; Mohammed, A. Overcoming Variants Resistance in Monoclonal Antibody for Antiviral Therapy. Preprints2023, 2023110307. https://doi.org/10.20944/preprints202311.0307.v1
Mustafa, M.; Alzebair, A.; Mohamednoor, H.; Mohammed, A. Overcoming Variants Resistance in Monoclonal Antibody for Antiviral Therapy. Preprints 2023, 2023110307. https://doi.org/10.20944/preprints202311.0307.v1
Mustafa, M.; Alzebair, A.; Mohamednoor, H.; Mohammed, A. Overcoming Variants Resistance in Monoclonal Antibody for Antiviral Therapy. Preprints2023, 2023110307. https://doi.org/10.20944/preprints202311.0307.v1
APA Style
Mustafa, M., Alzebair, A., Mohamednoor, H., & Mohammed, A. (2023). Overcoming Variants Resistance in Monoclonal Antibody for Antiviral Therapy. Preprints. https://doi.org/10.20944/preprints202311.0307.v1
Chicago/Turabian Style
Mustafa, M., Hanan Mohamednoor and Ahmed Mohammed. 2023 "Overcoming Variants Resistance in Monoclonal Antibody for Antiviral Therapy" Preprints. https://doi.org/10.20944/preprints202311.0307.v1
Abstract
Monoclonal antibody (mAb) therapy has revolutionized the treatment of various diseases, including cancer and autoimmune disorders. However, the emergence of SARS-CoV-2 variants, as well as other pathogenic variants, poses challenges in maintaining the therapeutic efficacy of mAbs. In this mini review article, we aim to explore the strategies to overcome variants resistance in mAb therapy against viral infections. Firstly, we discuss the mechanisms through which variants can evade the neutralizing effects of mAbs. Understanding these mechanisms is crucial in developing targeted approaches to combat resistance. Next, we delve into the strategies being pursued to address variants resistance. These include developing new mAbs or antibody cocktails that target multiple epitopes, engineering mAbs with improved binding affinities or enhanced neutralizing capabilities, and exploring alternative therapeutic modalities such as bispecific antibodies or antibody-drug conjugates. Furthermore, we highlight the role of computational modeling and artificial intelligence in predicting variant escape mutations and aiding in the design of more effective mAbs. Additionally, we examine the importance of continuous surveillance and monitoring of emerging variants to inform treatment strategies. This article emphasizes the urgent need for proactive approaches to tackle variants resistance in mAb therapy. By combining innovative design strategies, computational modeling, and vigilant surveillance, we can maintain the therapeutic effectiveness of mAbs and stay ahead in the battle against evolving pathogens and viral infections.
Biology and Life Sciences, Biology and Biotechnology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
